Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill aims to lower prescription drug prices in the United States by aligning them with prices paid in other wealthy countries. Within 30 days of enactment, the Secretary of Health and Human Services must propose new rules requiring pharmaceutical manufacturers to set U.S. prices comparable to those in developed nations, and the bill directs federal agencies to allow individual importation of lower-cost drugs from countries with cheaper medications. The legislation also instructs the Attorney General and Federal Trade Commission to pursue enforcement actions against anticompetitive practices by drug companies, while requiring the departments of Commerce and Health and Human Services to study whether manufacturers engage in unfair pricing practices that force American patients to subsidize global research. There is no specific funding amount allocated in the bill text, though it requires a study to be completed within 180 days of enactment. The bill affects pharmaceutical manufacturers and American patients paying for prescription drugs, and it was introduced by Representative Khanna along with cosponsors from both parties.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.